Factor VIII Products and Inhibitor Development in Severe Hemophilia A

2013432 citationsJournal Articlebronze Open Access

Authors

Samantha C. Gouw · University Medical Center Utrecht

Johanna G. van der Bom · Sanquin

Rolf Ljung · Skåne University Hospital

Carmen Escuriola · Goethe University Frankfurt

Ana Rosa Cid · Sociedad Española de Trombosis y Hemostasia

Ségolène Claeyssens‐Donadel · Centre Hospitalier Universitaire de Toulouse

Chris Van Geet

Abstract

Recombinant and plasma-derived factor VIII products conferred similar risks of inhibitor development, and the content of von Willebrand factor in the products and switching among products were not associated with the risk of inhibitor development. Second-generation full-length recombinant products were associated with an increased risk, as compared with third-generation products. (Funded by Bayer Healthcare and Baxter BioScience.).

Topics & Keywords

Hemophilia Treatment and Research Platelet Disorders and Treatments Blood Coagulation and Thrombosis Mechanisms

Publication Details

Published in: New England Journal of Medicine

Volume 368, Issue 3, pp. 231-239

DOI: 10.1056/nejmoa1208024

Field-Weighted Citation Impact: 36.97

Command Palette

Factor VIII Products and Inhibitor Development in Severe Hemophilia A

Authors

Abstract

Topics & Keywords

Publication Details